spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  PI3K 

 HSMN NewsFeed - 31 Dec 2024
Kazia Therapeutics Provides Update on Paxalisib Regulatory Pathway Following Type C Meeting with FDA
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 6 Apr 2022
FDA approves Novartis Vijoice(R) (alpelisib) as first and only treatment for select patients with PIK3CA-Related Overgrowth Spectrum (PROS)
Biopharmaceuticals FDA
 HSMN NewsFeed - 23 Jan 2020
iOnctura Raises EUR 15 Million in Series A Financing to Progress its Pipeline into Clinical Development
Biopharmaceuticals Oncology Venture Capital Personnel
 HSMN NewsFeed - 22 Aug 2019
Erasca Announces Key Leadership Team Appointments and Recruits World-Class Research and Development Advisory Board
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 6 May 2019
FogPharma Strengthens New Modality Drug Hunting Team with Appointment of Howard Stern as Chief Scientific Officer and Peter Fekkes as Vice President of Discovery Bioscience
Biopharmaceuticals Personnel
 HSMN NewsFeed - 2 Apr 2019
Petra Pharma Strengthens Management Team with Recent Leadership Appointments
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 20 Mar 2019
Petra Pharma announces licensing agreement with Takeda Pharmaceutical Company
Biopharmaceuticals Licensing
 HSMN NewsFeed - 7 Aug 2018
Infinity Pharmaceuticals Appoints Samuel Agresta, M.D., M.P.H. as Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 16 Jul 2018
MEI Pharma Promotes David M. Urso to Chief Operating Office
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 15 Jun 2018
MEI Pharma Presents Clinical Data on ME-401 at the European Hematology Association Congress
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 Mar 2018
Maura Dickler, M.D., to become Vice President of Late Phase Development at Lilly Oncology
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 8 Mar 2018
Infinity Pharmaceuticals Announces Additions to Board of Directors and Clinical Leadership Team and Establishes Scientific Advisory Board
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 23 Feb 2018
Kazia Receives FDA Orphan Designation for GDC-0084
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 3 Apr 2017
MEI Pharma Announces Appointment of Brian Drazba as Chief Financial Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 9 Mar 2017
OncoResponse Announces Final Closing of $22.5M Series A Financing Round
Biopharmaceuticals Oncology Personnel Venture Capital
 HSMN NewsFeed - 20 Jan 2017
Verastem Announces Executive Leadership Appointments and Changes
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 2 Nov 2016
Verastem Licenses Duvelisib from Infinity Pharmaceuticals
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 31 Oct 2016
Novogen Acquires Privately-held Neuro-oncology Company to Support Development of GDC-0084 in Glioblastoma
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 11 Feb 2016
Incyte Announces Decision to Discontinue JANUS Studies of Ruxolitinib plus Capecitabine in Patients with Advanced or Metastatic Pancreatic Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Sep 2015
Infinity Expands Pipeline with Addition of IPI-549, an Immuno-Oncology Development Candidate for the Treatment of Solid Tumors
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 2 Sep 2015
Exosome Diagnostics Raises $17.6 Million in Second Round Series B Financing
Diagnostics Venture Capital
 HSMN NewsFeed - 18 Dec 2014
Verastem Appoints Daniel Paterson as Chief Operating Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 5 Nov 2014
FDA Grants Orphan Drug Designation to Merrimack Pharmaceuticals' MM-141 for the Treatment of Pancreatic Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 19 Sep 2014
European Commission Grants Marketing Authorization for Gilead’s Zydelig(R) (Idelalisib) for the Treatment of Chronic Lymphocytic Leukemia and Follicular Lymphoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 4 Aug 2014
RestorGenex Appoints Mark Weinberg, MD, MBA Senior Vice President of Clinical Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 9 Jul 2014
RestorGenex Announces Management Changes
Biopharmaceuticals Dermatology Ophthalmology Personnel
 HSMN NewsFeed - 3 Jun 2014
Curis Announces Executive Management Transition
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 14 Jan 2014
ARIAD and Medinol Announce Initiation of Two Registration Trials of the NIRsupreme(TM) Ridaforolimus-Eluting Stent for Use in Coronary Artery Disease
Devices Interventional Cardiology
 HSMN NewsFeed - 24 Jul 2013
Verastem Receives Orphan Drug Designation from the U.S. FDA for Defactinib in Mesothelioma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 6 Jun 2013
Verastem Appoints Robert Forrester as Chief Executive Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 10 May 2013
Curis Announces Approval of Erivedge(R) in Australia
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 26 Apr 2013
Curis Announces Erivedge(R) Receives Positive CHMP Opinion for Conditional Approval in European Union
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 19 Feb 2013
Curis Appoints Ali Fattaey, Ph.D. as President and Chief Operating Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 14 Feb 2013
Verastem Files for Orphan Disease Status for VS-6063 in Mesothelioma
Biopharmaceuticals Oncology Regulatory FDA
 HSMN NewsFeed - 22 Jan 2013
Verastem Promotes Chief Operating Officer Robert Forrester to President
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 28 Nov 2012
Curis Announces Worldwide In-Licensing of IAP Inhibitor GDC-0917 From Genentech
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 6 Jun 2011
Merck and ARIAD Announce Presentation of Results of Phase III SUCCEED Trial at American Society of Clinical Oncology Annual Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 25 May 2011
FDA Approves Trial of Pathway Therapeutics, Inc. Cancer Drug; $7.5 Million Financing in Place to Advance Novel PI3K/mTOR Inhibitor Portfolio
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 28 Apr 2011
Arno Therapeutics Announces the Appointment of Mr. Glenn Mattes as President and Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Mar 2011
Paloma Pharmaceuticals Update on Ocular Clinical and Oncology Programs
Biopharmaceuticals Ophthalmology Oncology
 HSMN NewsFeed - 22 Feb 2011
Gilead Sciences to Acquire Calistoga Pharmaceuticals for $375 Million
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 18 Jan 2011
ARIAD Announces Oral Ridaforolimus Achieved Primary Endpoint of Improved Progression-Free Survival in Patients with Metastatic Soft-Tissue or Bone Sarcomas in the Phase 3 SUCCEED Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 Nov 2010
Semafore Pharmaceuticals Receives FDA Orphan Drug Designation for SF1126 in the Treatment of Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 29 Jul 2010
Calistoga Pharmaceuticals Appoints Langdon L. Miller, M.D., Executive Vice President, Research & Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 21 Jul 2010
Keryx Biopharmaceuticals, Inc. Announces Appointment of Joseph Feczko, M.D. to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 30 Jun 2010
Calistoga Pharmaceuticals Raises $40 Million in Series C Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 17 Jun 2010
Aquinox Pharmaceuticals Completes US $25 Million Series B Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 8 Apr 2010
Aeterna Zentaris Announces Initiation of Phase 3 Registration Trial with Perifosine in Refractory Advanced Colorectal Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Apr 2010
Keryx Receives FDA Fast Track Designation for KRX-0401 (Perifosine) for the Treatment of Refractory Advanced Colorectal Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 18 Dec 2009
Aeterna Zentaris Announces Termination of Agreement with sanofi-aventis U.S. for the Development, Commercialization and Licensing of Cetrorelix in Benign Prostatic Hyperplasia
Biopharmaceuticals Urology
 HSMN NewsFeed - 7 Dec 2009
AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia
Biopharmaceuticals Urology
 HSMN NewsFeed - 2 Dec 2009
AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 2 Dec 2009
Keryx Receives FDA Fast Track Designation for KRX-0401 (Perifosine) for the Treatment of Relapsed/Refractory Multiple Myeloma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 16 Sep 2009
Keryx Biopharmaceuticals Receives Orphan-Drug Designation for KRX-0401 (Perifosine) for the Treatment of Multiple Myeloma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 4 Aug 2009
Keryx Biopharmaceuticals Settles License Dispute With Alfa Wassermann
Biopharmaceuticals Licensing Litigation
 HSMN NewsFeed - 8 Jul 2009
Intellikine Completes $51 Million Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 5 May 2009
Calistoga Pharmaceuticals Raises $30 Million in Series B Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 11 Mar 2009
Calistoga Pharmaceuticals Announces Appointment of Clifford J. Stocks as Chief Business Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 Mar 2009
FDA Accepts Investigational New Drug (IND) Application for Tigris Pharmaceutical's GGTI-2418
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 22 Dec 2008
Myriad Genetics Launches Sixth Personalized Medicine Product, Prezeon -- to Reveal PTEN Status
Diagnostics Oncology
 HSMN NewsFeed - 8 Oct 2008
Calistoga Pharmaceuticals Appoints Carol G. Gallagher, Pharm. D., Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Mar 2008
EntreMed Announces 2008 Corporate and Clinical Program Priorities
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Feb 2008
Calistoga Pharmaceuticals Announces Appointment of R. Lee Douglas, 22-Year Biotechnology/Pharmaceutical Industry Veteran, to Its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Jan 2008
Calistoga Pharmaceuticals Announces Completion of Its Series A Financing -- Investors Increased Funding by 25% to Total $26.2 Million
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 3 Aug 2007
Semafore Pharmaceuticals Names Veteran Life Sciences Executive Edward L. Jacobs as Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 12 Jun 2007
Aquinox Pharmaceuticals completes US $ 14.5 million Series A financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 2 Jun 2007
Targeted, Oral Agent Enzastaurin Shows Favorable Results in Late-Stage Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Jun 2007
Semafore Pharmaceuticals Appoints Dr. Ullrich Schwertschlag Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 Mar 2007
Exelixis Files IND Application for XL147
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Oct 2006
Kyowa Hakko Grants Keryx Biopharmaceuticals Exclusive Rights to UCN-01, a Novel, Anticancer Agent in Phase II Clinical Development
Biopharmaceuticals Licensing
Return to NewsFeed  

 Additional items found! 4

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 4 additional stories matching:
PI3K
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.